HIV-1 envelope glycoprotein

Jiang S, Lin K, Strick N, Neurath AR (1993) Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41. Biochem Biophys Res Commun 195 533-538... 

Cormier EG, Persuh M, Thompson DA, et al. Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gpl20. Proc Natl Acad Sci U S A 2000 97(ll) 5762-5767. 

Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins fusogens, antigens, and immunogens. Science 1998 280(5371) 1884-1888. 

The major breakthrough in our structural knowledge of the HIV-1 envelope glycoprotein came in 1997 when the X-ray structure of the fusion-active form of gp41 was reported (35-37). Because it is inherently difficult to crystallize envelope glycoproteins, a protein-dissection approach was applied to derive substructures from the N- and C-terminal regions of the ectodomain termed N-36 and C-34. The structure indicates that the N-36/C-34 complex forms a hexahelical bundle consisting of a parallel trimeric coil-coil... 

Jiang S, Lin K, Lu M (1998) A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the HIV-1 envelope glycoprotein. J Virol 72 10213-10217... 

Milligan, E.D., O Connor, K.A., Nguyen, K.T. et al. (2001). Intrathecal HIV-1 envelope glycoprotein gpl20 induces enhanced pain states mediated by spinal cord proinflammatory cytokines. J. Neurosci. 21 2808-19. 

Wexler-Cohen Y, Ashkenazi A, Viard M et al (2010) Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. FASEB J 24 4196-4202... 

Vives RR, Imberty A, Sattentau QJ, Lortat-Jacob H. Heparan sulfate targets the HIV-1 envelope glycoprotein gpl20 coreceptor binding site. J Biol Chem 2005 280 21353-21357. 

Balabanian, K., Harriague, J., Decrion, C., Lagane, B., Shorte, S., Baleux, F., et al. 2004. CXCR4-tropic HIV-1 envelope glycoprotein functions as a viral chemokine in unstimulated primary CD4+ T lymphocytes. J. Immunol. 173,7150-7160. 

Dimitrov AS, Xiao X, Dimitrov DS, Blumenthal R. Early intermediates in HIV-1 envelope glycoprotein-mediated fusion triggered by CD4 and coreceptor complexes. J Biol Chem 2001 7 7. 

Cormier, E. G., Persuh, M., Thompson, D. A., Lin, S. W., Sakmar, T. P., Olson, W. C., et al. (2000). Specific interaction ofCCRS amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gpl20. Proceedings of the National Academy of Sciences of the United States of America, 97(11), 5762—5767. 

Navenot, J.M. et al. (2001) Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins differences in primary structural requirements for RANTES, MIP-1 alpha, and vM IP-II Binding. Journal of Molecular Biology, 313 (5), 1181-1193. 

Broder, C. C., Dimitrov, D. S., Blumenthal, R., and Berger, E. A. (1993) The block to HIV-1 envelope glycoprotein-mediated membrane fusion in animal cells expressing human CD4 can be overcome by a human cell component(s). Virology 193, 483-491. 

Puri A, Hug P, Munoz-Barroso I, Blumenthal R. Human erythrocyte glycolipids promote HIV-1 envelope glycoprotein-mediated fusion of CD4+ cells. Biochem Biophys Res Commun. 1998 242(l) 219-225. 

Ciardo A, Meldolesi J. Effects of the HIV-1 envelope glycoprotein gpl20 in cerebellar cultures. [Ca ]i increases in a glial cell subpopulation. Eur / Neurosci. 1993 5(12) 1711-1718. 

O. Andersen, A. M. Sorensen, S. E. Svehag, E. Fenouillet, Conglutinin binds the HIV-1 envelope glycoprotein gp 160 and inhibits its interaction with cell membrane CD4. Scand J. Immunol 1991,33, 81-88. 

---